NGeneBio

NGeneBio is a leading molecular diagnostics (MDx) and companion diagnostics (CDx) company that develops and provides next-generation sequencing (NGS)-based in vitro diagnostic (IVD) panels and clinical analysis software (SW). NGeneBio is a joint venture between Genecurix and Korea Telecom. In 2016, the company launched its NGS-based hereditary breast/ovarian cancer panel (BRCAaccuTestTM) and clinical analysis software (NGeneAnalysisTM). The product lineup includes BRCA NGS panels for PARP inhibitor CDx testing and solid tumor/hematological cancer NGS panels, along with a clinical data analysis software platform. The company’s mission is to deliver clinically validated NGS-based IVD/CDx products/services to the global market, integrating innovative bioinformatics and software development capabilities.